

Ohio Addictions Roundtable
June 3, 2016
Meeting Minutes

Present: Joyce Starr- OhioMHAS; Brad Lander-Talbot Hall; Jim Evans-Meridian; Carol Kasha-Ciallella- Recovery and Prevention Resources Delaware/Morrow; John Ellis- University of Akron; Sabrina Jones- LCADA-Way; Karen Olmhauser- MHR SB of Lucas County; Ed O'Neal- Abraxas; Steve Walkenhorst- Health Experience

Phone: Robert Carlson- Wright State University;

Guest: N/A

I. Old Business/Reporting:

- a. **Minutes** from May 6, 2016 Approved
- b. **Medication Assisted Treatment:**
 - i. J. Starr shared information on behalf of M. Hurst MD. He had indicated receiving some feedback from physicians in the field regarding the **new Pharmacy and Medical Board rules** concerning DATA 2000 medications. The rules may interfere with the disciplines ability to treat with their own discretion. B. Lander PhD cited recent correspondence from OhioAMA to the field. J. Starr referenced OhioBWC addressing overprescribing of opioid medications that has impacted over-rx practices. The Roundtable discussed strategies on how to best engage in dialogue with these stakeholders:
 1. RT to gain clarity on physician concerns.
 2. Convene a subcommittee inclusive of RT, representative from OhioAMA, Key physicians.
 - ii. J. Ellis illuminated statewide inconsistencies in how **County jails allow for continuation of MATs** (methadone, buprenorphine) while incarcerated. J. Starr will see if the issue can be made an agenda item at State Sheriffs meeting.
 - iii. B. Lander presented information on new **Long Acting Buprenorphine Implants** available after FDA approval. All agreed the new formulation has some practical applicability to the field is used correctly. The group came up with the following questions for clarity:
 1. Do they self titrate at the end of their life cycle (i.e. can they self taper for ease of withdrawal)?
 2. Are pregnant women eligible?
 3. How does this medication impact the prescribers DEA Waver caps?
 4. Are their known contra-indications for prescribing?
 5. Will this on-board medication complicate trauma medicine scenarios?J. Starr and B. Lander will follow-up with questions responses.
- c. **State Grants Management System:** J. Starr shared information on new state grant management systems being rolled out. Group shared some concern with frequency of state changes in electronic grants management processes.
- d. **Rules:** Group discussed assessment rules that allow for a Mini Assessment. Questions include:

- i. How do these new rules interface with other accrediting entities (e.g. CARF/ Joint Commission)?
- ii. Where to build “triggers” in electronic health records for the Mini-Assess. AT Survey?

e. MAT Usage Survey:

- i. **B. Lander PhD** walked through responses and data from the MAT Usage Survey. Special concerns were given to not generalize the data based on the small sample size and non-scientific nature of the survey. One of the more prominent results suggested AoD treatment providers have low confidence in the community buprenorphine/suboxone prescribers. This bias impacts the accommodating of MAT involved clients into some treatment programs.

The RT agreed to gain more reliable data via a larger sample size. Next Steps include:

- 1. Summarize current survey and disseminate these “preliminary” findings through the e-update (J. Ellis)
 - 2. Determine a strategy for generating a larger sample size (ASI, Sampling Agency, Epidemiology sites through OSAM, etc.). S. Starr from OhioMHAS will be invited to the next RT meeting to assist with these logistics.
- f. **Membership:** Group agreed to send an announcement that the RT is accepting applications for new members. The application will be linked to the announcement (j. Ellis)

II. New Business:

III. Next Meeting: Friday July 1, 2016 (via Conference Call)

- a. Agenda-
 - i. Increase MAT Use survey Sample- Strategy
 - ii. Membership

Respectfully submitted- J. Ellis